This study was aimed to compare and analyze Celltrion and Samsung Biologics, which contribute to human health and welfare through successful business management in COVID-19 era, by using ser-M model. Both companies have established the foundation of business development and production for antibody drugs during the corporate founding and leapfrogging phases, and have made rapid growth and business performance in Covid era. Their business strategies and performance played a major role in the global public health crisis called the Corona Pandemic. As a biopharmaceutical company, Celltrion have developed and manufactured neutralizing antibody. As a contract development manufacturing organization(CDMO), Samsung Biologics manufactured neutralizing antibodies and messenger ribonucleic acid vaccine(mRNA vaccine). Both companies have shown remarkable outcomes in drug supply chain. In management mechanisms, the subject, environment, and resources of both companies were studied. It was confirmed that the business performance was obtained through subject’s advancement, leadership, entrepreneurship, judgment, and decision-making. It is obvious that covid-19 pandemic caused a radical change of the environment and affected as a favorable circumstance to pharma and CDMO companies. Both companies have built up foundation for sustainable business through resource innovation such as technological advancement, portfolio diversification, and production capacity expansion in COVID era. If a sustainable management mechanism is established based on the brand value, technology, and capital of the company advanced in COVID era, it will be able to catch up the business achievement and performance of large pharmaceutical companies.